Abeona Therapeutics Inc ROCE
What is the ROCE of Abeona Therapeutics Inc?
The ROCE of Abeona Therapeutics Inc is -42.98%
What is the definition of ROCE?
Return on capital employed (ROCE) is a financial ratio that measures a company’s profitability and the efficiency with which its capital is used.
= EBIT / (assets - current liabilities)
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE of companies in the Health Care sector on NASDAQ compared to Abeona Therapeutics Inc
What does Abeona Therapeutics Inc do?
abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t
Companies with roce similar to Abeona Therapeutics Inc
- Turning Point Therapeutics Inc has ROCE of -43.12%
- Cerevel Therapeutics has ROCE of -43.07%
- Global Metals has ROCE of -43.04%
- Forma Therapeutics has ROCE of -43.04%
- Protalix BioTherapeutics has ROCE of -43.03%
- HEXO Corp has ROCE of -43.00%
- Abeona Therapeutics Inc has ROCE of -42.98%
- Netlist has ROCE of -42.93%
- The Very Good Food has ROCE of -42.86%
- Ambow Education Ltd has ROCE of -42.79%
- Amaero Intl Ltd has ROCE of -42.78%
- Kismet Resources has ROCE of -42.76%
- Artelo Biosciences has ROCE of -42.69%